Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer
Vijayalaxmi Gupta, Jeff Hirst, Shariska Petersen, Katherine F. Roby, Meghan Kusch, Helen Zhou, Makena Clive, Andrea Jewell, Harsh B. Pathak, Andrew K. Godwin, Andrew J. Wilson, Marta A. Crispens, Emily Cybulla, Alessandro Vindigni, Katherine C. Fuh, Dineo Khabele
Topics & Concepts
OlaparibCancer researchOvarian cancerHomologous recombinationPARP inhibitorMedicineSynthetic lethalityCancerHistone deacetylase inhibitorDNA repairHistone deacetylasePoly ADP ribose polymeraseBiologyInternal medicineHistoneDNAPolymeraseGeneticsPARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentSirtuins and Resveratrol in Medicine